Taiwan Food and Drug Administration published Guidelines for Decentralized Measures for the Implementation of Drug Clinical Trials. Below is a summary of the guidelines:
- Purpose and Concept: The document begins with an introduction that outlines the purpose and concept of decentralized measures in clinical trials.
- General Considerations: Section 2 discusses general considerations when implementing decentralized measures, including reducing face-to-face interactions, the impact on data integrity, reasons for implementation, and…
More details on this document can be found on the RegASK Platform.